Omid Hamid教授:黑色素瘤免疫治疗一线应用疗效更佳

2018-08-30 佚名 肿瘤资讯

由北京大学肿瘤医院和CSCO黑色素瘤专家委员会主办的2018第四届北京黑色素瘤国际研讨会在京成功举办。20余位国际级顶尖专家齐聚一堂,与国内医生共同探讨黑色素瘤治疗热点和焦点话题。肿瘤资讯特邀Omid Hamid教授共同探讨免疫治疗在黑色素瘤中的应用。

由北京大学肿瘤医院和CSCO黑色素瘤专家委员会主办的2018第四届北京黑色素瘤国际研讨会在京成功举办。20余位国际级顶尖专家齐聚一堂,与国内医生共同探讨黑色素瘤治疗热点和焦点话题。肿瘤资讯特邀Omid Hamid教授共同探讨免疫治疗在黑色素瘤中的应用。

Omid Ha mid教授Angeles临床研究所转化研究和免疫治疗中心主任黑色素瘤和I期临床研究中心主任擅长免疫治疗和I期药物研发主要研究双特异性抗体,适应性T细胞治疗和联合免疫治疗黑色素瘤 BRAF/MEK靶向治疗,抗CTLA4单抗,抗PD-1/L1单抗治疗的研究中作出重大贡献

帕博利珠单抗开创免疫治疗新高度

2018年ASCO会议中,黑色素瘤患者应用帕博利珠单抗的5年生存数据达到前所未有的新高。10年前,黑色素瘤5年生存率小于10%,如今已大于40%。可以说,免疫治疗为黑色素瘤带来革命性的胜利,显着降低复发及死亡风险,副作用小,使患者明显获益。免疫治疗在晚期黑色素瘤患者中的显着获益也为其在辅助治疗中的研究奠定基础,辅助免疫治疗可以显着降低患者的复发风险。免疫治疗获批用于临床后,更多患者可以因此受益,且其输注方便,免疫治疗毒副作用较小,患者的耐受性较好,无需集中在少数大医院,病人能够有更多的时间与家人共处,这也提高了患者的生活质量。帕博利珠单抗的在中国获批的适应症为黑色素瘤患者,国外的适应症还包括肾癌、肺癌、霍奇金瘤等多种肿瘤患者。目前我们已经进入了癌症免疫治疗的新纪元,将覆盖更多的瘤种。

免疫治疗一线应用疗效确切显着

2018年ASCO会议上,一项汇总分析的数据,一线接受免疫治疗取得客观疗效的患者,疾病缓解时间最长,目前关于背后的原因尚未明确,是否是因为患者有更高的肿瘤突变负荷。但毫无疑问,免疫治疗已经成为黑色素瘤一线治疗的标准。今后需要思考的是,哪些患者需要在一线使用免疫联合治疗,哪些患者适合免疫单药治疗,以及是否在进展后开始联合治疗,尚需进一步研究探索。

免疫治疗或优于靶向治疗

这是过去5年肿瘤医生一直关注和探索达问题。一项研究对比了伊匹木单抗联合纳武利尤单抗和达拉非尼联合曲美替尼,然而这一研究并不能回答所有的问题。抗PD-1/L1单药,或联合CTLA4单抗,或BRAF抑制剂联合MEK抑制剂,哪个是合适的一线治疗方案呢?我们需要探索能个体化给患者带来最大获益的治疗方案。亚组分析的数据显示,靶向治疗用于肿瘤负荷较大、合并多处转移的,并不能带来长期的获益。此外,近期一项发布在《新英格医学》杂志的数据显示,对于合并中枢神经系统转移的患者,免疫联合治疗对比靶向治疗,可以显着改善PFS和ORR,显然对于这类患者,免疫治疗更为合适。就我个人而言,如果患者能够耐受免疫治疗,单药或联合,则应该优选免疫治疗。然而对于不能耐受免疫治疗的患者或需要进行类固醇治疗或疾病进展迅速的患者,最佳的一线治疗方案仍需进一步探讨。

祝贺帕博利珠单抗中国上市,开启中国免疫治疗实践之路

经验源于实践,帕博利珠单抗在美国获批较早,我们积累了相对比较成熟的经验。帕博利珠单抗刚刚进入中国,对于中国医生而言,在刚开始治疗时应遵循指南,合理应用。根据我们的经验,免疫治疗疗效较好,部分患者可以获得持久的疗效,且毒副作用较小,耐受性较好,我相信中国医生在应用过程中也会逐步体会到这一创新疗法的卓越疗效。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1680552, encodeId=d0b616805527c, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Fri Jun 28 11:53:00 CST 2019, time=2019-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342567, encodeId=920534256e17, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Tue Sep 04 06:43:03 CST 2018, time=2018-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558920, encodeId=6efc15589206a, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Sep 01 11:53:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564929, encodeId=bf031564929cf, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Sep 01 11:53:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031886, encodeId=4cf51031886e9, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Thu Aug 30 23:53:00 CST 2018, time=2018-08-30, status=1, ipAttribution=)]
    2019-06-28 sunylz
  2. [GetPortalCommentsPageByObjectIdResponse(id=1680552, encodeId=d0b616805527c, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Fri Jun 28 11:53:00 CST 2019, time=2019-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342567, encodeId=920534256e17, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Tue Sep 04 06:43:03 CST 2018, time=2018-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558920, encodeId=6efc15589206a, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Sep 01 11:53:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564929, encodeId=bf031564929cf, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Sep 01 11:53:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031886, encodeId=4cf51031886e9, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Thu Aug 30 23:53:00 CST 2018, time=2018-08-30, status=1, ipAttribution=)]
    2018-09-04 1e145228m78(暂无匿称)

    学习了,谢谢作者分享!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1680552, encodeId=d0b616805527c, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Fri Jun 28 11:53:00 CST 2019, time=2019-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342567, encodeId=920534256e17, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Tue Sep 04 06:43:03 CST 2018, time=2018-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558920, encodeId=6efc15589206a, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Sep 01 11:53:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564929, encodeId=bf031564929cf, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Sep 01 11:53:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031886, encodeId=4cf51031886e9, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Thu Aug 30 23:53:00 CST 2018, time=2018-08-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1680552, encodeId=d0b616805527c, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Fri Jun 28 11:53:00 CST 2019, time=2019-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342567, encodeId=920534256e17, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Tue Sep 04 06:43:03 CST 2018, time=2018-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558920, encodeId=6efc15589206a, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Sep 01 11:53:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564929, encodeId=bf031564929cf, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Sep 01 11:53:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031886, encodeId=4cf51031886e9, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Thu Aug 30 23:53:00 CST 2018, time=2018-08-30, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1680552, encodeId=d0b616805527c, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Fri Jun 28 11:53:00 CST 2019, time=2019-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342567, encodeId=920534256e17, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Tue Sep 04 06:43:03 CST 2018, time=2018-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558920, encodeId=6efc15589206a, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Sep 01 11:53:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564929, encodeId=bf031564929cf, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Sep 01 11:53:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031886, encodeId=4cf51031886e9, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Thu Aug 30 23:53:00 CST 2018, time=2018-08-30, status=1, ipAttribution=)]
    2018-08-30 内科新手

    谢谢梅斯提供这么好的信息,学到很多

    0

相关资讯

免疫治疗用于黑色素瘤新辅助和辅助治疗的新近进展

由中国临床肿瘤学会(CSCO)和北京大学肿瘤医院联合举办的“CSCO 2018第四届北京黑色素瘤国际研讨会”在北京成功召开。本次会议云集了国际黑色素瘤领域的顶尖专家学者,与中国关注黑色素瘤事业发展的临床医生、科研人员一道,分享交流全球的最新研究进展,切磋探讨黑色素瘤诊治和研究中的实际问题,为我国学者提供了一个广泛交流与学习的平台。【肿瘤资讯】有幸邀请到GustaveRoussy癌症研究所Egger

JAMA Dermat:什么?这样做可将黑色素瘤风险降低40%!

近日,一项新的研究表明,防晒霜可以降低40%的黑色素瘤风险。这是第一项针对40岁以下年轻人使用防晒霜与黑色素瘤风险之间关系的研究,国际著名学术期刊JAMA Dermatology以大篇幅报道了这一成果!

ANN ONCOL:免疫检查点抑制剂耐药的黑色素瘤中分离出的T细胞依然具有功能

接近一半的转移性黑色素瘤患者接受免疫检查点抑制剂治疗时只出现短期疗效或无疗效。ANN ONCOL近期发表了一篇文章,研究接受免疫检查点抑制剂治疗后进展患者的免疫系统是否还可以出现肿瘤特异性免疫反应。

NEJM:突破!联合免疫疗法显著缩小黑色素瘤的脑转移

《NEJM》杂志最近报道了一项突破性成果:德克萨斯大学MD Anderson癌症中心的研究人员发现,PD-1单抗Opdivo(nivolumab)联合CTLA-4单抗Yervoy(ipilimumab)治疗黑色素瘤脑转移,在中位随访14.0个月的94例患者中,扩散到其大脑中的黑色素瘤范围得到显著缩小。

ANN ONCOL:贝伐单抗用于高复发风险黑色素瘤患者的辅助治疗

贝伐单抗是血管内皮生长因子的单克隆抗体,用于晚期改善实体瘤患者的预后。ANN ONCOL近期发表了一篇文章,评估贝伐单抗用于高复发风险黑色素瘤患者辅助治疗的效果。

NEJM:纳武单抗联合易普利姆玛用于黑色素瘤脑转移

研究认为纳武单抗联合易普利姆玛可改善黑色素瘤脑转移患者病情,具有显著的颅内疗效